Two Sigma Investments LP Invests $560,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Two Sigma Investments LP acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 135,807 shares of the company's stock, valued at approximately $560,000. Two Sigma Investments LP owned 0.18% of Trevi Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TRVI. Summit Investment Advisors Inc. lifted its stake in shares of Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock worth $26,000 after buying an additional 2,894 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics in the fourth quarter worth approximately $49,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Trevi Therapeutics in the fourth quarter valued at approximately $82,000. ProShare Advisors LLC increased its holdings in shares of Trevi Therapeutics by 86.4% during the 4th quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock worth $85,000 after buying an additional 9,589 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in Trevi Therapeutics in the 4th quarter valued at about $89,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 18.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on TRVI shares. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of Trevi Therapeutics in a report on Tuesday, May 20th. Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Finally, Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $18.63.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded down $0.08 during trading hours on Thursday, hitting $6.17. The stock had a trading volume of 2,963,417 shares, compared to its average volume of 1,348,411. The firm's 50-day moving average price is $6.27 and its two-hundred day moving average price is $5.06. Trevi Therapeutics, Inc. has a 52 week low of $2.36 and a 52 week high of $7.48. The company has a market capitalization of $616.34 million, a P/E ratio of -14.02 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. As a group, analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.